Please assess the completion status of the following clinical trial:

Trial Title: A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma,~* Ages \>/= 1 and \</= to 30 years at the time of initial diagnosis~* Undergoing asparaginase treatment for ALL or lymphoblastic lymphoma~* Documented Grade 2 or higher hypersensitivity reaction to native or pegylated E. coli asparaginase or Calaspargase pegol~* Must have two remaining weeks of native E. coli asparaginase treatment or 1 remaining dose of either Pegaspargase or Calaspargase pegol~* Direct bilirubin less than or equal to Grade 2~* Amylase and lipase within normal limits (per institutional standards)~* Signed informed consent by the patient is greater than or equal to 18 years or by the parent if the patient is younger than 18 years old.~Exclusion Criteria:~-

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 30 Years
- Healthy Volunteers: f

Study Arms:
- Open-Label Erwinaze (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).